UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2005
FAVRILLE, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | | 000-51134 | | 33-0892797 |
(State or Other Jurisdiction of
Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
10421 Pacific Center Court, Suite 150
San Diego, California | | 92121 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 526-8000
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
As previously announced in Favrille, Inc.’s May 9, 2005 press release, Favrille will be presenting the results of a physician-sponsored Phase 2 clinical trial using FavId® following autologous stem cell transplantation in patients with follicular cell and mantle cell non-Hodgkin’s lymphoma (NHL) during a poster session on May 15, 2005 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The presentation is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) | Exhibits. |
| |
| Exhibit No. | | Description |
| 99.1 | | Poster Presentation by Favrille, Inc. |
2
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 13, 2005 | Favrille, Inc. |
| |
| By: | /s/ Tamara A. Seymour | |
| Name: | Tamara A. Seymour |
| Title: | Chief Financial Officer |
3
EXHIBIT INDEX
Exhibit No. | | Description |
99.1 | | Poster Presentation by Favrille, Inc. |
4
